Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cingulate Inc ( (CING) ) has shared an announcement.
Between November 21, 2025 and January 2, 2026, Cingulate Inc. issued multiple tranches of common stock to a lender in exchange for portions of outstanding debt, with share prices ranging from $3.39 to $4.13. The unregistered stock-for-debt exchanges reduce the company’s debt load but dilute existing shareholders, reflecting an ongoing effort to manage its capital structure without raising new cash in the public markets.
The most recent analyst rating on (CING) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Cingulate Inc stock, see the CING Stock Forecast page.
Spark’s Take on CING Stock
According to Spark, TipRanks’ AI Analyst, CING is a Neutral.
The score is held back mainly by weak financial performance (pre-revenue, widening losses, and persistent cash burn). Offsetting this are meaningful positive corporate milestones (FDA NDA acceptance and added financing) and a modestly constructive technical picture, while valuation is difficult to support due to negative earnings and no dividend.
To see Spark’s full report on CING stock, click here.
More about Cingulate Inc
Average Trading Volume: 172,882
Technical Sentiment Signal: Hold
Current Market Cap: $29.33M
Learn more about CING stock on TipRanks’ Stock Analysis page.